Medicare will cover weight-loss drugs under a deal between the Trump administration and drugmakers Eli Lilly and Novo Nordisk to cut prices for blockbuster diabetes and anti-obesity drugs. Why it matters: About 10% of Medicare enrollees will be newly eligible for coverage of GLP-1 drugs because of the deal,

President Trump appeared in the oval office with executives from the companies behind GLP1 weight loss drug Wegovy and Zepbound to announce new costs for Medicare recipients and price reductions set t...

Coverage of the drugs for obesity will expand to Medicare patients starting next year, according to the administration, which said some lower prices also will be phased in for patients without covera...